View our masking and visitation guidelines based on current rates of respiratory illnesses in the community.

Our new building on the hospital campus, Forest B, is open. Families and visitors can park in the new Forest B garage next to Emergency.

Clinical Trial Search block Test

001 Healthy Kids Demo Trial 02

001 Healthy Kids Demo Trial 01

Phase: II/III

What is the goal of the study?

To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of 9-ING-41 as a single agent and in combination with Irinotecan in pediatric patients with refractory malignancies. 2. To describe the toxicity profile and DLT of 9-ING-41 as a single agent and in combination with Irinotecan in pediatric patients with refractory malignancies. 3. To characterize the pharmacokinetics of 9-ING-41 as a single agent and in combination with Irinotecan when administered to pediatric patients with refractory malignancie

Who can participate in the study?

Everyone

Study Team:

Study Team Member: John Kruger, jkrugerTEST@seattlechildrens.org